Not FDA-approved

Skin & aging

Melanotan II

Evidence

Not approved; illegal sales

Class

Synthetic melanocortin receptor agonist

/

Melanotan II

KEY TAKEAWAY

Melanotan II is an unapproved synthetic peptide sold online for tanning. The FDA and other regulators warn against it because of side effects and concerns about changes to moles and skin cancer risk.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

An unapproved synthetic melanocortin peptide

Used for

Skin tanning (unapproved)

Key fact

Regulators warn against it; it is sold illegally in many countries

Route

Injection (unregulated)

Evidence strength

Not approved; illegal sales

What it is

What it is

Melanotan II is a lab-made peptide related to alpha-MSH that acts on several melanocortin receptors.

How it works

How it works

It stimulates pigment-producing cells, which darkens the skin. Its action on other melanocortin receptors also explains effects on appetite and sexual arousal.

Regulatory status

Regulatory status

Melanotan II is not approved anywhere as a medicine. Regulators have issued public warnings about products sold for tanning.

What it is used for

What it is used for

Marketed illegally for tanning. It has no approved medical use.

Side effects and risks

Side effects and risks

Nausea, flushing, fatigue, darkening and changes in moles, and spontaneous erections are reported. Reports of skin cancer in users raise safety concerns.

Citations

Citations

Primary literature for this entry is being compiled.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo